HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on ORIC Pharmaceuticals but lowers the price target from $14 to $13.

August 15, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ORIC Pharmaceuticals' price target has been lowered from $14 to $13 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the stock, which could counterbalance the negative sentiment to some extent.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100